Our science

Towards much safer and more effective treatment options in cancer

Antibody-based therapies have revolutionized cancer therapy and have contributed to significantly improved overall survival rates following cancer diagnosis. As the cancer therapy landscape matures further, the future medical need will increasingly shift to effective treatments with superior safety profiles, reducing the severe side effects seen with the current-generation products or avoiding them altogether. At VERAXA, we are building an R&D organization suited to meet this future demand.

A strong history in ADC development

VERAXA has established a strong position in ADC development. Developing safe and efficacious ADCs requires:

  • technologies to identify the “right” antibody for the disease context
  • the ability to bioengineer the position of payloads
  • efficient click chemistry for fast, uniform and stable conjugation of such payloads

VERAXA is the only company with an integrated approach that combines functional antibody screening with bioconjugation technology. We harvest our suite of innovative technologies to develop novel ADCs with a wide therapeutic window and favorable pharmacokinetics. We solve the central challenges of antibody screening and ADC development.

Combinatorial-gated Design

VERAXA has established a new technology platform with BiTACs. BiTACs benefit from a novel antibody architecture with combinatorial-gated design for cancer targeting and built-in safety features.

Learn More

Functional antibody screening

Our droplet-based microfluidics technology allows to harvest the entire immune repertoire to identify internalizing antibodies for ADCs even against challenging targets.

Further applications include the identification of receptor modulating antibodies.

Learn More

Positional intelligence

Our genetic code expansion technology delivers ultimate precision and flexibility for payload positioning while being minimally invasive and highly efficient.

Learn more

Bioorthogonal click chemistry

Our highly reactive click group yields uniform ADCs with outstanding stability under bio-compatible conditions while minimizing excess payload.

Learn more